To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Landos Biopharma goes public
Landos Biopharma, a developer of treatments for patients with autoimmune diseases, has raised about $100 million for its IPO after pricing its 6.25 million shares at $16 per share.
